Clinical trial
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed…
NCT00418886 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00418886 |
|---|---|
| Title | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients |
| Official title | A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC |
| Acronym | ZEAL |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer, Lung Cancer |
| Intervention type | Drug |
| Interventions | Vandetanib, Pemetrexed |
| Enrollment | 698 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Feb 14, 2023 |
| First posted | Jan 5, 2007 |
| Last update posted | Dec 31, 2024 |
| Countries | Argentina, Australia, Belgium, Colombia, France, Germany, Greece, Hong Kong, India, Israel, Italy, Mexico and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: